Galeterone as a Treatment for Castration Resistant Prostate Cancer

The objectives of this study are to compare the efficacy and safety of daily oral treatment with galeterone (Experimental Arm) to daily oral treatment with enzalutamide (Control Arm) in adult male patients with androgen receptor (AR) splice variant-7 (ARV7), metastatic (M1) castration resistant prostate cancer (CRPC) who have not yet received chemotherapy, abiraterone.

April 07, 2016